CPL
GILD icon

Capital & Planning LLC’s Gilead Sciences GILD Stock Holding History

Capital & Planning LLC’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$139 – 82
2026
Q1 		$139 Buy
+1
New +$140 ﹤0.01% 167
2025
Q1 		– Sell
-1
Closed -$92 – 88
2024
Q4 		$92 Buy
+1
New +$90 ﹤0.01% 191

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital & Planning LLC's GILD Position: Q2 2026 in Review

Capital & Planning LLC sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 1 share — an estimated $139 sold.

Capital & Planning LLC first reported a position in GILD in Q4 2024 and held it in 2 quarters. The position peaked at $139 in Q1 2026. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Capital & Planning LLC reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
  • Capital & Planning LLC sold 1 Gilead Sciences share in Q2 2026, an estimated $139.
  • Capital & Planning LLC first reported a position in Gilead Sciences in Q4 2024 and held it in 2 quarters.
  • Capital & Planning LLC's Gilead Sciences position peaked at $139 in Q1 2026.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Capital & Planning LLC's 13F filing for Q2 2026, filed 2 Sep 2026.